Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Response to pneumococcal vaccination in multiple myeloma.

Renaud L, Schraen S, Fouquet G, Guidez S, Demarquette H, Nudel M, Cayssials E, Bories C, Herbaux C, Systchenko T, Faucompré JL, Machet A, Sabirou F, Levy A, Bobin A, Richez V, Moya N, Gruchet C, Desmier D, van de Wyngaert Z, Carpentier B, Manier S, Facon T, Harding S, Leleu X.

Cancer Med. 2019 Jul;8(8):3822-3830. doi: 10.1002/cam4.2253. Epub 2019 May 30.

2.

Memory and plasticity impairment after binge drinking in adolescent rat hippocampus: GluN2A/GluN2B NMDA receptor subunits imbalance through HDAC2.

Drissi I, Deschamps C, Fouquet G, Alary R, Peineau S, Gosset P, Sueur H, Marcq I, Debuysscher V, Naassila M, Vilpoux C, Pierrefiche O.

Addict Biol. 2019 May 6:e12760. doi: 10.1111/adb.12760. [Epub ahead of print]

PMID:
31056842
3.

Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

Leleu X, Fouquet G, Richez V, Guidez S, Duhamel A, Machuron F, Karlin L, Kolb B, Tiab M, Araujo C, Meuleman N, Malfuson JV, Bourquard P, Lenain P, Roussel M, Jaccard A, Pétillon MO, Belhadj-Merzoug K, Lepeu G, Chrétien ML, Fontan J, Rodon P, Schmitt A, Offner F, Voillat L, Cereja S, Kuhnowski F, Rigaudeau S, Decaux O, Humbrecht-Kraut C, Frayfer J, Fitoussi O, Roos-Weil D, Eisenmann JC, Dorvaux V, Voog EG, Attal M, Moreau P, Avet-Loiseau H, Hulin C, Facon T.

Clin Cancer Res. 2019 Jul 15;25(14):4224-4230. doi: 10.1158/1078-0432.CCR-18-3642. Epub 2019 May 3.

PMID:
31053600
4.

Lessons to Learn From Low-Dose Cyclosporin-A: A New Approach for Unexpected Clinical Applications.

Flores C, Fouquet G, Moura IC, Maciel TT, Hermine O.

Front Immunol. 2019 Mar 28;10:588. doi: 10.3389/fimmu.2019.00588. eCollection 2019. Review.

5.

Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.

Lemal R, Fouquet G, Terriou L, Vaes M, Livideanu CB, Frenzel L, Barete S, Canioni D, Lhermitte L, Rossignol J, Arock M, Dubreuil P, Lortholary O, Hermine O.

J Allergy Clin Immunol Pract. 2019 Sep - Oct;7(7):2387-2395.e3. doi: 10.1016/j.jaip.2019.03.039. Epub 2019 Apr 5.

PMID:
30954641
6.

Enhanced Renewal of Erythroid Progenitors in Myelodysplastic Anemia by Peripheral Serotonin.

Sibon D, Coman T, Rossignol J, Lamarque M, Kosmider O, Bayard E, Fouquet G, Rignault R, Topçu S, Bonneau P, Bernex F, Dussiot M, Deroy K, Laurent L, Callebert J, Launay JM, Georgin-Lavialle S, Courtois G, Maroteaux L, Vaillancourt C, Fontenay M, Hermine O, Côté F.

Cell Rep. 2019 Mar 19;26(12):3246-3256.e4. doi: 10.1016/j.celrep.2019.02.071.

7.

Carfilzomib weekly 20/56 mg/m2 , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma.

Richez V, Gruchet C, Guidez S, Fouquet G, Azais I, Durand G, Javaugue V, Brigaud A, Plasse F, Diolez J, Machet A, Moya N, Gardeney H, Franques P, Bobin A, Levy A, Sabirou F, Bonnin A, Dieval C, Primault S, Barrier J, Fleck E, Bouyier S, Daras C, Princet I, Bauwens D, Legros L, Fuzibet JG, Gil A, Bridoux F, Avet-Loiseau H, Leleu X.

Am J Hematol. 2019 Jan;94(1):E17-E20. doi: 10.1002/ajh.25327. Epub 2018 Nov 25. No abstract available.

8.

Serotonin, hematopoiesis and stem cells.

Fouquet G, Coman T, Hermine O, Côté F.

Pharmacol Res. 2019 Feb;140:67-74. doi: 10.1016/j.phrs.2018.08.005. Epub 2018 Aug 11. Review.

PMID:
30107202
9.

Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma.

Fouquet G, Guidez S, Richez V, Stoppa AM, Le Tourneau C, Macro M, Gruchet C, Bobin A, Moya N, Syshenko T, Sabirou F, Levy A, Franques P, Gardeney H, Karlin L, Benboubker L, Ouali M, Vedovato JC, Ferre P, Pavlyuk M, Attal M, Facon T, Leleu X.

Oncotarget. 2018 May 8;9(35):23890-23899. doi: 10.18632/oncotarget.25156. eCollection 2018 May 8.

10.

Signaling lymphocytic activation molecules Slam and cancers: friends or foes?

Fouquet G, Marcq I, Debuysscher V, Bayry J, Rabbind Singh A, Bengrine A, Nguyen-Khac E, Naassila M, Bouhlal H.

Oncotarget. 2018 Feb 26;9(22):16248-16262. doi: 10.18632/oncotarget.24575. eCollection 2018 Mar 23. Review.

11.

Role of IRF4 in resistance to immunomodulatory (IMid) compounds® in Waldenström's macroglobulinemia.

Bertrand E, Jouy N, Manier S, Fouquet G, Guidez S, Boyle E, Noel S, Tomowiak C, Herbaux C, Schraen S, Preudhomme C, Quesnel B, Poulain S, Leleu X.

Oncotarget. 2017 Dec 4;8(68):112917-112927. doi: 10.18632/oncotarget.22872. eCollection 2017 Dec 22.

12.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

Fouquet G, Karlin L, Macro M, Caillot D, Roussel M, Arnulf B, Pegourie B, Petillon MO, Mathiot C, Hulin C, Kolb B, Stoppa AM, Brechiniac S, Rodon P, Dib M, Tiab M, Richez V, Araujo C, Wetterwald M, Garderet L, Royer B, Perrot A, Benboubker L, Decaux O, Escoffre-Barbe M, Fermand JP, Moreau P, Avet-Loiseau H, Attal M, Facon T, Leleu X.

Ann Hematol. 2018 May;97(5):831-837. doi: 10.1007/s00277-018-3236-6. Epub 2018 Jan 12.

PMID:
29330561
13.

Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.

Fouquet G, Snell KI, Guidez S, Schraen S, Boyle E, Renaud L, Desmier D, Machet A, Moya N, Systchenko T, Gruchet C, Decaux O, Arnulf B, Fohrer C, Richez V, Kolb B, Macro M, Karlin L, Royer B, Pegourie B, Hebraud B, Caillot D, Perrot A, Moreau P, Facon T, Avet-Loiseau H, Dejoie T, Hulin C, Harding S, Leleu X.

Leuk Lymphoma. 2018 Mar;59(3):583-589. doi: 10.1080/10428194.2017.1339876. Epub 2017 Jul 12.

PMID:
28697637
14.

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.

Kendrick F, Evans ND, Arnulf B, Avet-Loiseau H, Decaux O, Dejoie T, Fouquet G, Guidez S, Harel S, Hebraud B, Javaugue V, Richez V, Schraen S, Touzeau C, Moreau P, Leleu X, Harding S, Chappell MJ.

Front Physiol. 2017 Mar 17;8:149. doi: 10.3389/fphys.2017.00149. eCollection 2017.

15.

Treatment of Newly Diagnosed Elderly Multiple Myeloma.

Fouquet G, Gay F, Boyle E, Bringhen S, Larocca A, Facon T, Leleu X, Palumbo A.

Cancer Treat Res. 2016;169:123-143. Review.

PMID:
27696261
16.

BACH2 promotes indolent clinical presentation in Waldenström macroglobulinemia.

Herbaux C, Bertrand E, Marot G, Roumier C, Poret N, Soenen V, Nibourel O, Roche-Lestienne C, Broucqsault N, Galiègue-Zouitina S, Boyle EM, Fouquet G, Renneville A, Tricot S, Morschhauser F, Preudhomme C, Quesnel B, Poulain S, Leleu X.

Oncotarget. 2016 Jun 7;8(34):57451-57459. doi: 10.18632/oncotarget.9917. eCollection 2017 Aug 22.

17.

IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.

Boyle E, Manier S, Lejeune J, Fouquet G, Guidez S, Bonnet S, Debarri H, Demarquette H, Dulery R, Gay J, Hennache B, Onraed B, Faucompré JL, Schraen S, Facon T, Avet-Loiseau H, Chevret S, Leblond V, Harding S, Leleu X.

Clin Cancer Res. 2016 Oct 15;22(20):5152-5158. Epub 2016 May 11.

18.

Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs.

Fouquet G, Debuysscher V, Ouled-Haddou H, Eugenio MS, Demey B, Singh AR, Ossart C, Al Bagami M, Regimbeau JM, Nguyen-Khac E, Naassila M, Marcq I, Bouhlal H.

Oncotarget. 2016 May 31;7(22):32493-503. doi: 10.18632/oncotarget.8679.

19.

RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation.

Bouhlal H, Ouled-Haddou H, Debuysscher V, Singh AR, Ossart C, Reignier A, Hocini H, Fouquet G, Al Baghami M, Eugenio MS, Nguyen-Khac E, Regimbeau JM, Marcq I.

Oncotarget. 2016 Mar 1;7(9):9832-43. doi: 10.18632/oncotarget.6954.

20.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benbouker L, Decaux O, Escoffre-Barbe M, Fermand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X; IFM (Intergroupe Francophone du Myélome).

Ann Oncol. 2016 May;27(5):902-7. doi: 10.1093/annonc/mdw017. Epub 2016 Jan 19.

21.

Lenalidomide is safe and active in Waldenström macroglobulinemia.

Fouquet G, Guidez S, Petillon MO, Louni C, Ohyba B, Dib M, Poulain S, Herbaux C, Martin A, Thielemans B, Brice P, Choquet S, Bakala J, Bories C, Demarquette H, Nudel M, Tournilhac O, Arnulf B, LeGouill S, Morel P, Banos A, Karlin L, Salles G, Leblond V, Leleu X.

Am J Hematol. 2015 Nov;90(11):1055-9. doi: 10.1002/ajh.24175. Epub 2015 Oct 6.

22.

[Pomalidomide for multiple myeloma].

Fouquet G, Macro M, Decaux O, Fohrer C, Guidez S, Demarquette H, Le Grand C, Prodhomme C, Renaud L, Bories C, Herbaux C, Karlin L, Roussel M, Benboubker L, Hulin C, Arnulf B, Leleu X.

Rev Med Interne. 2015 Sep;36(9):613-8. doi: 10.1016/j.revmed.2015.04.007. Epub 2015 Aug 6. Review. French.

PMID:
26257103
23.

G-CSF mobilizes CD34+ regulatory monocytes that inhibit graft-versus-host disease.

D'Aveni M, Rossignol J, Coman T, Sivakumaran S, Henderson S, Manzo T, Santos e Sousa P, Bruneau J, Fouquet G, Zavala F, Alegria-Prévot O, Garfa-Traoré M, Suarez F, Trebeden-Nègre H, Mohty M, Bennett CL, Chakraverty R, Hermine O, Rubio MT.

Sci Transl Med. 2015 Apr 1;7(281):281ra42. doi: 10.1126/scitranslmed.3010435.

PMID:
25834108
24.

[Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation].

Fouquet G, Amouzou K, Renaud L, Carpentier B, Simonnet A, Van de Wyngaert Z, Guidez S, Demarquette H, Seynave M, Deleplanque D, Yakoub-Agha I, Facon T, Leleu X.

Rev Med Interne. 2015 Jul;36(7):444-9. doi: 10.1016/j.revmed.2014.10.366. Epub 2014 Nov 5. French.

PMID:
25596921
25.

Pomalidomide for multiple myeloma.

Fouquet G, Bories C, Guidez S, Renaud L, Herbaux C, Javed S, Facon T, Leleu X.

Expert Rev Hematol. 2014 Dec;7(6):719-31. doi: 10.1586/17474086.2014.966074. Epub 2014 Sep 30. Review.

PMID:
25265911
26.

IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.

Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, Onraed B, Faucompré JL, Hennache B, Petillon MO, Mathiot C, Avet-Loiseau H, Facon T, Harding SJ, Moreau P, Leleu X.

Cancer. 2014 Dec 15;120(24):3952-7. doi: 10.1002/cncr.28946. Epub 2014 Aug 12. Erratum in: Cancer. 2015 Mar 1;121(5):800.

27.

Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.

Fouquet G, Guidez S, Herbaux C, Van de Wyngaert Z, Bonnet S, Beauvais D, Demarquette H, Adib S, Hivert B, Wemeau M, Berthon C, Terriou L, Coiteux V, Macro M, Decaux O, Facon T, Huglo D, Leleu X.

Clin Cancer Res. 2014 Jun 15;20(12):3254-60. doi: 10.1158/1078-0432.CCR-13-2910. Epub 2014 Apr 8.

28.

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation.

Fouquet G, Hebraud B, Garciaz S, Stoppa AM, Roussel M, Caillot D, Chrétien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Touzeau C, Tessoulin B, Fermand JP, Facon T, Attal M, Loiseau HA, Moreau P, Leleu X.

J Cancer. 2014 Mar 11;5(3):248-52. doi: 10.7150/jca.8541. eCollection 2014.

29.

[Smoldering multiple myeloma].

Fouquet G, Guidez S, Herbaux C, Demarquette H, Leleu X.

Rev Med Interne. 2014 Apr;35(4):243-9. doi: 10.1016/j.revmed.2013.08.004. Epub 2013 Sep 17. Review. French.

PMID:
24050785
30.

Mixed phenotype acute leukaemia with Burkitt-like cells and positive peroxidase cytochemistry.

Duployez N, Debarri H, Fouquet G.

Br J Haematol. 2013 Oct;163(2):148. doi: 10.1111/bjh.12514. Epub 2013 Aug 9. No abstract available.

PMID:
23930593
31.

Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.

Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaux C, Guidez S, Michel J, Perrot A, Serrier C, Miljkovic D, Avet Loiseau H, Facon T, Hulin C, Leleu X.

Cancer. 2013 Oct 15;119(20):3680-6. doi: 10.1002/cncr.28274. Epub 2013 Aug 6.

32.

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma.

Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chrétien ML, Arnulf B, Szalat R, Garderet L, Benajiba L, Pegourie B, Regny C, Royer B, Caulier A, Stoppa AM, Garciaz S, Touzeau C, Chaleteix C, Fermand JP, Loiseau HA, Facon T, Attal M, Moreau P; Intergroupe Francophone du Myélome (IFM).

Leukemia. 2013 Nov;27(11):2242-4. doi: 10.1038/leu.2013.101. Epub 2013 Apr 5. No abstract available.

PMID:
23558525
33.

Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia.

Poulain S, Herbaux C, Bertrand E, Decambron A, Fouquet G, Boyle E, Gay J, Manier S, Duthilleul P, Roumier C, Leleu X.

Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):202-4. doi: 10.1016/j.clml.2013.02.008. Epub 2013 Mar 7. Review.

PMID:
23473949
34.

Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.

Boyle EM, Fouquet G, Manier S, Gauthier J, Noel MP, Borie C, Facon T, Elalamy I, Leleu X.

Expert Rev Hematol. 2012 Dec;5(6):617-26; quiz 627. doi: 10.1586/ehm.12.52. Review.

PMID:
23216532
35.

Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens.

Manier S, Barthelemy M, Fouquet G, Prod'homme C, Le Ray E, Samarcq P, Noel MP, Terriou L, Facon T, Cossment C, Boulanger F, Leleu X.

Leukemia. 2012 Dec;26(12):2552-4. doi: 10.1038/leu.2012.138. Epub 2012 May 25. No abstract available.

PMID:
22627696
36.

Effect of streptozotocin-induced diabetes mellitus on release of vasoactive intestinal polypeptide from rodent small intestine.

Nowak TV, Chey WW, Chang TM, Weisbruch JP, Fouquet G.

Dig Dis Sci. 1995 Apr;40(4):828-36.

PMID:
7720477

Supplemental Content

Loading ...
Support Center